Servier announces a strategic worldwide licensing agreement for Black Diamond Therapeutics' BDTX-4933 for solid tumors for an upfront payment of $70 million and up to $710 million in milestone ...
Servier and Black Diamond Therapeutics (BDTX) announced a strategic worldwide licensing agreement for BDTX-4933, a potential best-in-class ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results